First-in-Human trial tests custom vaccine against deadly brain cancer
NCT ID NCT06342908
Summary
This is a small, early-stage study to see if a personalized vaccine is safe for patients with a rare and aggressive brain tumor called H3 G34-mutant glioma. The vaccine is made from the patient's own immune cells and is designed to teach the body to attack the tumor. Researchers will give the vaccine to up to 6 adults to check for side effects and see if it triggers an immune response.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE HEMISPHERIC GLIOMA, H3 G34-MUTANT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.